Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in...

Full description

Bibliographic Details
Main Authors: Larrayoz, Marta, Pio, Ruben, Pajares, María J, Zudaire, Isabel, Ajona, Daniel, Casanovas, Oriol, Montuenga, Luis M, Agorreta, Jackeline
Format: Online
Language:English
Published: Backwell Publishing Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992079/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992079/

Similar Items